mouse ccl2 elisa kit (Bioss)
Structured Review

Mouse Ccl2 Elisa Kit, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse ccl2 elisa kit/product/Bioss
Average 93 stars, based on 1 article reviews
Images
1) Product Images from "Adeno-associated viruses (AAVs) induce dose-dependent neonatal ventriculomegaly following intracerebroventricular administration"
Article Title: Adeno-associated viruses (AAVs) induce dose-dependent neonatal ventriculomegaly following intracerebroventricular administration
Journal: bioRxiv
doi: 10.64898/2025.12.30.697113
Figure Legend Snippet: AAVs induce dose-dependent CSF dyshomeostasis. (A) CSF CCL2 concentrations measured by ELISA at P7.5 following P0.5 ICV injection of escalating AAV doses. (B, C) Parenchymal microglial response. (B) Representative Iba1 immunostaining in P7.5 brain sections. (C) Quantification of Iba1⁺ cell density in parenchymal regions. (D, E) ChP microglial response. (D) Representative Iba1 immunostaining in the ChP. (E) Quantification of Iba1⁺ cell density in the ChP. (F) CSF transthyretin (TTR) concentrations measured by ELISA at P7.5 following P0.5 ICV injection of escalating AAV doses. (G–J) ChP protein analysis by immunoblot. (G) Representative blot for TTR and GFP in ChP lysates. (H) Relative GFP expression. (I) Relative TTR expression. (J) Correlation analysis between GFP and TTR levels in individual samples. (K, L) CSF ion disruption following inflammation. (K) Experimental timeline for LPS-induced inflammation and CSF collection in adult mice. (L) CSF potassium (K⁺) concentration measured by ICP-MS.
Techniques Used: Enzyme-linked Immunosorbent Assay, Injection, Immunostaining, Western Blot, Expressing, Disruption, Concentration Assay
Figure Legend Snippet: AAV induces dose-dependent embryonic and adult ventriculomegaly. (A) Experimental timeline for assessing acute AAV2/5 transfection 24 hours post in utero ICV injection. (B) Representative image confirming robust AAV2/5 transfection in the embryonic ChP at E14.5 (24 hours post-injection). (C) Timeline for evaluating the effects of escalating AAV2/5 doses via in utero ICV injection at E13.5, with analysis at E16.5. (D) Embryonic survival rates at E16.5. Numbers indicate the proportion of surviving embryos per litter. (E) Representative coronal sections of E16.5 embryonic brains showing transgene expression (GFP) and ventricular morphology. (F, G) CSF analysis from E16.5 embryos. (F) CCL2 concentrations. (G) Transthyretin (TTR) concentrations. (H) Timeline for assessing the effects of escalating AAV2/5 doses via ICV injection in adult mice (3-day endpoint). (I) Representative coronal sections at the level of the posterior anterior commissure (pAC; dashed outline) showing lateral ventricle morphology in adult brains. (J, K) Representative sagittal section demonstrating the differential cellular tropism of AAV2/5. (J) ChP-specific transfection by low-dose AAV2/5. (K) A more permissive tropism of high-dose AAV2/5, with ectopic GFP signal also observed in hippocampal CA1 region.
Techniques Used: Transfection, In Utero, Injection, Expressing